FGEN - FibroGen Inc Stock Price, Fair Value and News

$0.40+0.05 (+14.29%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

FGEN Price Action

Last 7 days

21.2%

Last 30 days

14.3%

Last 90 days

-2.4%

Trailing 12 Months

-42.0%

FGEN RSI Chart

FGEN Valuation

Market Cap

40.3M

Price/Earnings (Trailing)

-0.33

Price/Sales (Trailing)

0.27

EV/EBITDA

0.9

Price/Free Cashflow

-0.32

FGEN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

FGEN Fundamentals

FGEN Revenue

Revenue (TTM)

147.8M

Rev. Growth (Yr)

15.45%

Rev. Growth (Qtr)

16.02%

FGEN Earnings

Earnings (TTM)

-121.8M

Earnings Growth (Yr)

73.14%

Earnings Growth (Qtr)

-9.91%

FGEN Profitability

Operating Margin

71.82%

EBT Margin

-84.74%

Return on Equity

54.57%

Return on Assets

-46.06%

Free Cashflow Yield

-313.16%

FGEN Investor Care

Shares Dilution (1Y)

2.47%

Diluted EPS (TTM)

-1.23

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	116.1M	130.6M	155.0M	147.8M
2022	257.7M	263.1M	122.9M	140.7M
2021	191.1M	205.8M	220.6M	235.3M
2020	257.1M	108.4M	119.3M	176.3M
2019	204.9M	352.5M	356.7M	256.6M
2018	133.5M	147.2M	135.6M	213.0M
2017	184.3M	125.3M	135.8M	131.0M
2016	192.8M	161.5M	172.1M	183.2M
2015	136.0M	166.6M	172.5M	180.8M
2014	111.0M	119.9M	128.7M	137.6M
2013	0	0	0	102.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About FibroGen Inc

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

WEBSITE	fibrogen.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	592

FibroGen Inc Frequently Asked Questions

What is the ticker symbol for FibroGen Inc? What does FGEN stand for in stocks?

FGEN is the stock ticker symbol of FibroGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of FibroGen Inc (FGEN)?

As of Fri Dec 20 2024, market cap of FibroGen Inc is 40.31 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of FGEN stock?

You can check FGEN's fair value in chart for subscribers.

Is FibroGen Inc a good stock to buy?

The fair value guage provides a quick view whether FGEN is over valued or under valued. Whether FibroGen Inc is cheap or expensive depends on the assumptions which impact FibroGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FGEN.

What is FibroGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, FGEN's PE ratio (Price to Earnings) is -0.33 and Price to Sales (PS) ratio is 0.27. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. FGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on FibroGen Inc's stock?

In the past 10 years, FibroGen Inc has provided -0.345 (multiply by 100 for percentage) rate of return.